Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1

Conditions

Neoplasm Metastasis 39Lymphoma 27Multiple Myeloma 24Colorectal Neoplasms 20Leukemia, Myeloid, Acute 18Melanoma 13Lung Neoplasms 13Prostatic Neoplasms 12Pancreatic Neoplasms 12Ovarian Neoplasms 12Breast Neoplasms 11Sarcoma 10Triple Negative Breast Neoplasms 9Lymphoma, Non-Hodgkin 9Fallopian Tube Neoplasms 9Burkitt Lymphoma 9Urinary Bladder Neoplasms 8Neuroblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Glioma 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Myelodysplastic Syndromes 7Lymphoma, Follicular 7Endometrial Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5

Interventions

Specimen Handling 3Nivolumab 3Ipilimumab 3Biopsy 3prednylidene 2pembrolizumab 2deltacortene 2Prednisone 2Magnetic Resonance Spectroscopy 2CTLA-4 Antigen 2talimogene laherparepvec 1oblimersen 1cixutumumab 1avelumab 1antineoplaston AS 2-1 1antineoplaston A10 1Tacrolimus 1Sirolimus 1Salts 1Radiosurgery 1Octreotide 1Imatinib Mesylate 1Everolimus 1Complementary Therapies 1Biological Therapy 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Carcinoma, Merkel Cell × Biopsy × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT05947500 2026-05-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡